Genetically Engineered Multivalent Proteins for Targeted Immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27009744.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0246 and PMC identifier 4947414.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes. Clin Cancer Res; 22(14); 3419-21. ©2016 AACRSee related article by Vallera et al., p. 3440.
Medical subject headings
- Neoplasms
- Proteins